A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy

Immunotherapies have recently gained traction as highly effective therapies in a subset of late-stage cancers. Unfortunately, only a minority of patients experience the remarkable benefits of immunotherapies, whilst others fail to respond or even come to harm through immune-related adverse events. F...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajakumar, Timothy, Horos, Rastislav, Jehn, Julia, Schenz, Judith, Muley, Thomas, Pelea, Oana, Hofmann, Sarah, Kittner, Paul, Kahraman, Mustafa, Heuvelman, Marco, Sikosek, Tobias, Feufel, Jennifer, Skottke, Jasmin, Nötzel, Dennis, Hinkfoth, Franziska, Tikk, Kaja, Daniel-Moreno, Alberto, Ceiler, Jessika, Mercaldo, Nathaniel, Uhle, Florian, Uhle, Sandra, Weigand, Markus A., Elshiaty, Mariam, Lusky, Fabienne, Schindler, Hannah, Ferry, Quentin, Sauka-Spengler, Tatjana, Wu, Qianxin, Rabe, Klaus F., Reck, Martin, Thomas, Michael, Christopoulos, Petros, Steinkraus, Bruno R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971493/
https://www.ncbi.nlm.nih.gov/pubmed/35361874
http://dx.doi.org/10.1038/s41698-022-00262-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971493/
https://www.ncbi.nlm.nih.gov/pubmed/35361874
http://dx.doi.org/10.1038/s41698-022-00262-y

Ejemplares similares